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Early gestational mesenchymal stem cell
secretome attenuates experimental
bronchopulmonary dysplasia in part via
exosome-associated factor TSG-6
Sushma Chaubey1, Sam Thueson1, Devasena Ponnalagu2, Mohammad Afaque Alam1, Ciprian P. Gheorghe3,
Zubair Aghai4, Harpreet Singh2,5 and Vineet Bhandari1*
Abstract
Background: Mesenchymal stem cells (MSCs) are promising tools for the treatment of human lung disease and
other pathologies relevant to newborn medicine. Recent studies have established MSC exosomes (EXO), as one of
the main therapeutic vectors of MSCs in mouse models of multifactorial chronic lung disease of preterm infants,
bronchopulmonary dysplasia (BPD). However, the mechanisms underlying MSC-EXO therapeutic action are not
completely understood. Using a neonatal mouse model of human BPD, we evaluated the therapeutic efficiency of
early gestational age (GA) human umbilical cord (hUC)-derived MSC EXO fraction and its exosomal factor, tumor
necrosis factor alpha-stimulated gene-6 (TSG-6).
Methods: Conditioned media (CM) and EXO fractions were isolated from 25 and 30 weeks GA hUC-MSC cultures
grown in serum-free media (SFM) for 24 h. Newborn mice were exposed to hyperoxia (> 95% oxygen) and were
given intraperitoneal injections of MSC-CM or MSC-CM EXO fractions at postnatal (PN) day 2 and PN4. They were
then returned to room air until PN14 (in a mouse model of severe BPD). The treatment regime was followed with
(rh)TSG-6, TSG-6-neutralizing antibody (NAb), TSG-6 (si)RNA-transfected MSC-CM EXO and their appropriate controls.
Echocardiography was done at PN14 followed by harvesting of lung, heart and brain for assessment of pathology
parameters.
Results: Systemic administration of CM or EXO in the neonatal BPD mouse model resulted in robust improvement
in lung, cardiac and brain pathology. Hyperoxia-exposed BPD mice exhibited pulmonary inflammation accompanied
by alveolar-capillary leakage, increased chord length, and alveolar simplification, which was ameliorated by MSC CM/
EXO treatment. Pulmonary hypertension and right ventricular hypertrophy was also corrected. Cell death in brain was
decreased and the hypomyelination reversed. Importantly, we detected TSG-6, an immunomodulatory glycoprotein, in
EXO. Administration of TSG-6 attenuated BPD and its associated pathologies, in lung, heart and brain. Knockdown of
TSG-6 by NAb or by siRNA in EXO abrogated the therapeutic effects of EXO, suggesting TSG-6 as an important
therapeutic molecule.
(Continued on next page)
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Conclusions: Preterm hUC-derived MSC-CM EXO alleviates hyperoxia-induced BPD and its associated pathologies, in
part, via exosomal factor TSG-6. The work indicates early systemic intervention with TSG-6 as a robust option for cell-
free therapy, particularly for treating BPD.
Keywords: Bronchopulmonary dysplasia, Mesenchymal stem cells, Wharton’s jelly, Secretome, Exosomes, Newborn,
Pulmonary hypertension, Hyperoxia-induced lung injury, TSG-6
Background
Bronchopulmonary dysplasia (BPD) is a serious long-term
complication of prematurity and the most common
chronic lung disease in infants who need respiratory sup-
port after birth [1]. Brain injury and pulmonary hyperten-
sion (PH) are common complications of BPD resulting in
increased morbidity and mortality [2–4]. There is no sin-
gle effective therapy for BPD, making it important to ex-
plore new strategies of treatment. Mesenchymal stromal
cell (MSC) therapy has been demonstrated to exert thera-
peutic effects in animal models of injury in the developing
lung [5, 6]; however, a better understanding of the most
appropriate cell type, optimal transplantation conditions
and importantly, mechanism of action of MSC transplant-
ation is required [7]. Beneficial effects of MSCs have been
reported even in the absence of significant engraftment of
donor cells in the recipient lungs following MSC therapy,
suggesting that the therapeutic mechanism of action are
mainly paracrine [5, 8, 9]. Several reports demonstrate
better protection of structural deficits in preclinical BPD
models using cell-free conditioned media (CM) of MSCs
over MSCs themselves [5, 10–12]. Administration of MSC
extracellular vesicles (EVs) has been reported to be benefi-
cial in a number of lung disease models [9, 12–17] and ex
vivo human lung models [15]. Willis et al group reported
that MSC exosomes (EXO) act, at least in part, through
modulation of lung macrophage phenotype, suppressing
lung inflammation and immune responses to favor proper
organ development [17]. The detailed mechanism of ac-
tion or specific molecules involved in the action of
MSC-CM EXO is yet to be reported.
Premature babies with extremely low birth weight
most at risk for developing BPD are usually born be-
tween 24 weeks (wks) gestational age (GA) and 30 wks
GA. Earlier studies demonstrate that higher levels of
CD34+ hematopoietic stem and progenitor cells (HSPC)
circulate in the blood of premature neonates, which may
be associated with accelerated recovery from lung injury
[18]. With the concept of using the human umbilical
cord (hUC) MSCs from these premature babies for their
therapy, we investigated the therapeutic efficiency of the
early GA UC-MSCs secretome, both CM and EXO, on
improvement in organ function and other markers of
BPD pathology. We isolated MSCs from Wharton’s jelly
(WJ) of hUC of premature neonates born at 25 wks and
30 wks GA to study whether the therapeutic effects are
mediated through MSC-derived CM/secretome, specific-
ally, EXO. MSC-CM and MSC-CM-derived EXO were
administered to a mouse model of hyperoxia-induced in-
jury that replicates human BPD [19–22]. We also identi-
fied MSC-secreted EXO factor tumor necrosis factor
alpha-stimulated gene-6 (TSG-6), an immunomodula-
tory molecule, and evaluated its efficiency in treatment
of BPD in our experimental mouse model. This strategy
was used to explore the possibility of administering se-
creted factors as an alternative to the use of live cells.
In the present study, treatment of BPD mice with early
GA UC-MSC-CM or EXO show robust decrease in lung
inflammation, morphometric deformations, cell death,
vascularization deficits, brain cell death and improved
PH. Hypomyelination and decreased astrocytes in brain
were reversed on intraperitoneal administration of
MSC-CM EXO. We report presence of TSG-6 protein
in the EXO fraction of 25 wks GA hUC MSC-CM. Intra-
peritoneal (i.p.) administration of TSG-6 improved BPD
pathology in lungs, heart and brain, thus indicating the
significance of its use in the systemic therapy of BPD.
Administration of EXO isolated from TSG-6 small inter-
fering ribonucleic acid (siRNA)-transfected MSCs abro-
gated the therapeutic effects of MSC-CM EXO in a BPD
model. Additionally, we demonstrate similar decrease in
EXO therapeutic effects in BPD mice on administration
of TSG-6 neutralizing antibody. Our results demonstrate
for the first time that TSG-6, found in the WJ MSC
secretome, is one of the important therapeutic mediators
for BPD and its associated pathologies, at least in part.
Methods
Animals
Wildtype (WT) C57BL/6 obtained from The Jackson La-
boratory (Bar Harbor, ME, USA) were maintained in a
breeding colony at Drexel University, Philadelphia, PA,
USA. Animal procedures were performed in accordance
with the NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal
Care and Use Committee (IACUC) of Drexel University.
Oxygen exposure and mouse model of BPD
Newborn (NB) pups were exposed to hyperoxia, along
with their mothers, in cages in an airtight Plexiglas
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chamber (OxyCycler; Biospherix, Redfield, NY, USA) as
described previously by our group [19, 20, 22–26]. Ex-
posure to > 95% oxygen from birth or postnatal day 1
(PN1) until PN4, corresponds to the saccular stage of
mouse lung development. At PN5, all animals were
placed in room air (RA) up to PN14, which corresponds
to the alveolar stage of mouse lung development, to
allow for a period of recovery. Using this experimental
model, NB WT mouse lungs at PN14 have the pheno-
type mimicking severe BPD in humans.
Isolation, expansion and characterization of hUC WJ
MSCs. UCs were collected from healthy donors after
their pre-term deliveries (25 and 30 wks GA) and imme-
diately transferred to the laboratory. The collection of
UC was approved by the Drexel University Institutional
Review Board with a waiver of consent, as UCs are con-
sidered discarded material. MSCs were isolated from the
WJ of hUC and expanded in MSC culture media, using
a modified protocol [27] (Additional file 1: Experimental
procedures). Characterization of UC-MSCs was per-
formed as per the International Society of Cell Therapy
(ISCT) guidelines. The UC-MSCs were characterized by
standard fluorescence-activated cell sorting (FACS) for
the expression of CD105, CD73 and CD90 and absence
of HLA-DR, CD19 and CD14 surface molecules.
UC-MSCs were differentiated for 21 days, into multiline-
age adipocytes, osteoblasts and chondroblasts, using spe-
cific differentiation media (StemPro Differentiation Kit,
Gibco by Life Technologies, Carlsbad, CA, USA) and
stained with Oil Red O, Alizarin S Red and Alcian Blue,
respectively (Additional file 1: Experimental procedures).
Preparation of UC MSC-CM, EXO and EXO-depleted CM
for injections
To obtain MSC-CM, UC-MSCs at passage 3, with 70–
80% confluency and cell equivalents of 0.76 × 106 were
washed three times with phosphate-buffered saline
(PBS). The complete media of the cell cultures were re-
placed with serum-free [without fetal bovine serum
(FBS)] DMEM:F12 containing 1% (v/v) penicillin/
streptomycin. After 24 h, the serum-free media (SFM)
were centrifuged (Eppendorf, Jericho, NY, USA) at 300 ×
g for 6 min at 4 °C, filtered through a 0.22 μm filter (Pall
Corporation, Port Washington, NY, USA) and stored at
−80 °C until use. For in vivo injections, the CM was con-
centrated tenfold using Amicon Ultra Centrifugal Filter
Device (Millipore, Billerica, MA, USA) with a 10 kDa
molecular weight cutoff. Total protein concentration of
the secretome was measured by BCA kit (Pierce, Rock-
ford, IL, USA) as per the manufacturer’s recommenda-
tions. A volume of 100 μl MSC-CM concentrate,
equivalent to a total of 10 μg MSC-CM protein per
mouse was injected via i.p. route at PN2 and PN4 to test
the potential therapeutic effect of the treatment. The
same amount of the concentrated DMEM:F12 media
served as control injections.
Isolation of EXO from UC MSC-CM was performed
using modified Thery’s protocol [28]. Briefly, the
UC-MSC CM from passage 3 and cell equivalents of
0.76 × 106 were centrifuged at 300 g followed by 2000 g
for 10 min at 4 °C and filtered through a 0.22 μm filter.
The filtrate was spun at 110,000 g for 2 h at 4 °C. The
pellet was washed in PBS and spun at 110,000 g for
1.5 h at 4 °C. The obtained pellet of EXO was resus-
pended in PBS. 100 μl of EXO suspension, equivalent to
a total of approximately 2.4 μg of MSC-CM EXO pro-
tein per mouse, and 4.5 × 108 and 2.88 × 107 particles
(for MSC-CM EXO 25 wks and 30 wks, respectively),
was injected via the i.p. route at PN2 and PN4. 100 μl of
PBS served as control.
EXO-depleted CM 25 wks was obtained by centrifuga-
tion of 25 wks GA UC-MSC CM at 300 g, followed by
2000 g for 10 min at 4 °C. The supernatant was filtered
through a 0.22 μm filter. The filtrate was spun at
110,000 g for 2 h at 4 °C. The EXO-depleted supernatant
obtained after ultracentrifugation was carefully collected
and concentrated tenfold using 10 kDa molecular weight
cutoff Amicon Ultra Centrifugal Filter Device (Millipore,
Billerica, MA, USA). Total protein concentration of the
EXO-depleted CM was measured by BCA kit (Pierce,
Rockford, IL, USA). A volume of 100 μl EXO-depleted
MSC-CM concentrate was injected via the i.p. route at
PN2 and PN4 to test the potential therapeutic effect of
the treatment.
Exosome dosing
Exosome preparations (100 μl of WJMSC-EXO) were
injected i.p. at PN2 and PN4 in our BPD model, after di-
luting with PBS to achieve a standard dosage per pup cor-
responding to the product generated by 0.7 × 106 MSCs
over 24 h (h). There is no established quantification
method for EXO-based therapeutics at present. Our ra-
tionale for choosing this EXO dose was based on other
pilot experiments in the lab and previous studies by other
groups, where they found that injecting mouse pups with
a bolus dose of concentrated MSC-CM corresponding to
the amount conditioned by 0.5 × 106 to 1 × 106 MSCs for
24 h − 36 h was sufficient to prevent lung injury and to re-
verse PH [10, 11, 29]. The particle count used in this study
was 4.5 × 108 particles for 25 wks EXO and 2.88 × 107 par-
ticles for 30 wks EXO, protein concentration 2.8 μg and
2.4 μg, respectively for each, obtained from CM from
MSCs grown in SFM, cell equivalent of 0.7 × 106 for 24 h.
Our dose is comparable to the recently published work by
Willis et al [17], which injected a dose comprising of par-
ticle count of 8.5 × 108 and protein concentration of
0.9 μg obtained from the MSC cell equivalent of 0.5 × 106
cells for 36 h (Additional file 1: Table S1). Exosomal
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preparations for different GA MSCs was prepared main-
taining identical conditions and handling to minimize the
residual non-exosomal protein contamination and to
maintain the consistency of the EXO fraction for both
25wks and 30 wks EXO for comparison.
Bronchoalveolar lavage (BAL)
The mouse pups were euthanized for aspiration of BAL
fluid (BALF) from the lungs. BALF total cell counts, ab-
solute neutrophil count, macrophage percentage and
total BALF protein was estimated as described in the
Additional file 1: Experimental procedures.
Tissue processing
The lung, heart and brain were excised after transcardiac
perfusion with ice-cold PBS. The lungs were processed as
previously described [19, 20, 22, 24]. The left lobes of lungs
were subjected to standard protocol for lung inflation
(25 cm) and fixed overnight in 4% paraformaldehyde (PFA)
at 4 °C [19, 20, 22, 24]. The right lobes of the lungs were
snap-frozen in liquid nitrogen and stored at −80 °C for bio-
chemical analysis. Heart and brain were paraffin-embedded
after overnight fixation in 4% PFA at 4 °C. Before embed-
ding, the brain was divided into four regions - olfactory
bulb, forebrain, mid brain and hind brain for analysis.
Lung morphometry
Five-micrometer-thick paraffin-embedded sections were
stained with hematoxylin and eosin (H&E) as previously
described [30]. A minimum of five randomly chosen
areas from each section were photographed with the
×200 magnification. Investigators were blinded to ex-
perimental groups for the analysis. Alveolar size was es-
timated from the mean chord length of the airspace, as
described previously [22, 26]. Alveolar septal wall thick-
ness was estimated using ImageJ software, adapting the
method for bone trabecular thickness, for the lung [26,
31, 32]. The mean alveolar area was calculated using the
method previously reported [33]. Number of branches,
junctions, junction voxels, triple points and quadruple
points were calculated using AnalyzeSkeleton program
from ImageJ. This plugin tags all pixel/voxels in a skel-
eton image and then counts all its junctions, triple and
quadruple points and branches. Junction voxels are de-
fined by having more than two neighbors. Number of
triple points and quadruple points depicts those cells
having more than three or four neighbors, respectively.
Western blot analysis, dot blot assay, terminal
deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) assay, immunofluorescence and
immunohistochemistry and enzyme-linked immunosorbant
assay (ELISA) for interleukin-6 (IL-6) in lung lysate
Described in Additional file 1: Experimental procedures.
Heart measurements for PH-induced right ventricular
hypertrophy (RVH)
Cross-section of paraffin-embedded heart from four to
six mice from each group were analyzed for measure-
ment of right ventricular (RV) to left ventricular (LV)
diameter ratio, [RV/LV] and RV to LV + interventricular
septa (IVS) ratio, [RV/(LV + IVS)], also called Fulton’s
index to quantitate the degree of PH-induced RVH, as
previously described [19, 26].
Echocardiography
Mouse pups at PN14 were anesthetized using i.p. keta-
mine/xylaxine injections (100/10 mg/kg mouse weight).
Echocardiography was performed in anesthetized mice
using the Vevo 2100 imaging system (Visual Sonics, To-
ronto, Canada) with a high frequency (18–38 MHz)
probe (VisualSonics MS400) with simultaneous ECG re-
cording. Visual sonic software analysis tool was used to
obtain pulmonary artery acceleration time (PAAT) and
PA ejection time (PAET) values. A short PAAT or small
PAAT/PAET ratio indicates high peak systolic PA pres-
sure, as previously described and validated [34, 35].
Transmission electron microscopy (TEM)
For EXO visualization and morphological assessment, an
aliquot from an EXO preparation (3–5 μl) was adsorbed
for 15 s to a formvar-carbon coated grid (Electron Mi-
croscopy Sciences, Hatfield, PA, USA). Excess liquid was
removed with Whatman Grade 1 filter paper (Sigma-Al-
drich, St. Louis, MO, USA) followed by staining for 15 s
with 2% uranyl acetate. Adsorbed exosomes were exam-
ined on a JEOL 1010 transmission electron microscope
(TEM), and images were recorded with a Hamamatsu
digital camera using a magnification of ×100,000 (Hama-
matsu, Photonics, Hamamatsu City, Japan).
Nanoparticle tracking analysis (NTA)
Size and concentration distributions of exosomes were
determined using nanoparticle tracking analysis (NS-300
NanoSight Instrument, Malvern Instruments Ltd., Mal-
vern, UK). NTA determines the Brownian motion of
nanoparticles in real-time to assess size and concentra-
tion utilizing a laser-illuminated microscopic technique
equipped with a 405 nm laser and a high sensitivity
digital camera system (sCMOS camera, Hamamatsu
Photonics, Hamamatsu, Japan).
EXO samples were diluted in vesicle-free PBS. Samples
were administered and recorded under controlled flow,
using the NanoSight syringe pump. Data acquisition and
processing were performed using NTA software version
2.3 build 0025. Background extraction was applied, and
automatic settings were employed to determine the mini-
mum expected particle size, minimum track length, and
blur settings. Since samples were diluted in ultrapure
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DPBS 0.0095 M (PO4) w/o Ca and Mg (Lonza, Basel,
Switzerland), viscosity settings for water were applied and
automatically corrected for the temperature used. Data
were obtained at camera-level 12 (shutter:600, gain: 350).
For each sample, three videos of 30 s duration at 25
frames per second were recorded and assigned a single
measurement in triplicates. Three sets of samples were
run, from which exosome distribution, size and mean con-
centration were calculated.
RNA isolation and quantitative real-time PCR (qRT-PCR) of
human lung tracheal aspirates and mouse lung tissues
Collection and processing of the human lung samples was
approved by the institutional review board of Thomas Jef-
ferson University Hospital. Human lung tracheal aspirates
(TA) were obtained from premature infants being mech-
anically ventilated in the first PN week with an in-dwelling
endotracheal tube. These infants had the final outcomes
of having the diagnoses of with or without BPD. Selected
clinical details are shown in Additional file 1: Table S2.
Pellets obtained from TA were subjected for total
RNA extraction using TRIZOL (Invitrogen, Carlsbad,
CA, USA) and RNAeasy kit (Qiagen, Hilden, Germany).
First-strand cDNA was synthesized with iScript cDNA
Synthesis kit for Real-Time-PCR (Bio-Rad, Hercules,
CA, USA) according to the manufacturer’s instructions.
Real-time PCR reaction was performed in a 20 μL vol-
ume with SYBR Green (Bio-Rad, Hercules, CA, USA)
with the use of pooled cDNA samples. Human TSG-6
primers (Applied Biosystems, Foster City, CA, USA)
used for the amplification: forward primer: ACTC
AAGTATGGTCAGCGTATTC (sense) and reverse pri-
mer: GCCATGGACATCATCGTAACT (antisense). hu-
man HPRT, forward primer 5′-TAT GGC GAC CCG
CAG CCC T-3’ reverse primer 5’-CAT CTC GAG CAA
GAC GTT CAG-3′.
RNA was isolated from excised mouse lung tissues
from RA, BPD and BPD groups injected with PBS,
MSC-CM EXO 25 wks, TSG-6 using TRIZOL (Invitro-
gen, Carlsbad, CA, USA) and RNAeasy kit (Qiagen, Hil-
den, Germany). For gene expression analysis of IL-6,
tumor necrosis factor alpha (TNF-α) and interleukin 1
beta (IL-1β), real-time PCR was performed using the fol-
lowing primers: IL-6: forward 5′-TGG GGC TCT TCA
AAA GCT CC-3′, reverse 5′-AGG AAC TAT CAC
CGG ATC TTC AA-3′; TNF-α: forward 5′- GGG TCG
CAC CAT GAA GGA G-3, reverse: 5′- GAA GTG GTA
GTG GTA GCT TTC G-3′; IL-1β: forward 5’ GCA
CTA CAG GCT CCG AGA TGA AC-3′, reverse:
5′-TTG TCG TTG CTT GGT TCT CCT TGT-3’
HPRT: forward: 5’-GCT GGT GAA AAG GAC CTC
T-3′, reverse: 5’-CAC AGG ACT AGA ACA CCT
GC-3′. The reaction was performed at 95 °C for 10 min
followed by a 40-cycle denaturation at 94 °C for 15 s,
annealing at 54 °C for 30 s and extension at 72 °C for
40 s, using a Real-Time System (Applied Biosystems,
Foster City, CA, USA).
Transfection of hMSCs with TSG-6 siRNA
hUC MSCs from passage 3 were thawed and plated at 200
cells/cm2 in multiple six-well plates in DMEM:F12 media
with antibiotics. The culture medium was changed every
2 days. After incubation for 4–5 days, when the cells were
~ 80% confluent, the cells were incubated in SFM for 12 h
followed by transfection with TSG-6 siRNA (sc-39,819;
Santa Cruz Biotechnology, Dallas, TX, USA) or negative
control [scrambled siRNA (scr siRNA)/control siRNA,
sc-37,007; Santa Cruz Biotechnology, Dallas, TX, USA]
using a commercial kit (Lipofectamine 3000 reagent; Invi-
trogen, Carlsbad,, CA, USA) as per the manufacturer’s in-
structions. A 5 μM stock solution of TSG-6 siRNA or
negative control (scr siRNA/control siRNA) was diluted
with reagent (Lipofectamine 3000 Reagent; Invitrogen,
Carlsbad,, CA, USA), which was further diluted with
transfection medium (siRNA Transfection medium, Santa
Cruz Biotechnology, Dallas, TX, USA). The mixture was
incubated for 30 min at room temperature. The mixture,
together with transfection medium, was added to the cells.
Sixteen hours later, the transfection medium was replaced
with DMEM:F12 media containing 10% FBS. hMSCs were
revived for 6 h. The culture was then incubated in
complete media with antibiotics for another 16 to 20 h.
For EXO isolation from the TSG-6 siRNA-transfected
MSCs, TSG-6 siRNA transfected MSCs were grown in
SFM for another 24 h. After 24 h, serum-free CM was col-
lected for isolation of TSG-6 siRNA EXO. To confirm
knockdown of TSG-6, RNA was extracted from scrambled
(scr) and TSG-6 siRNA-transfected MSCs (RNeasy Mini
Kit; Qiagen, Hilden, Germany) and assayed for TSG-6 by
real-time RT-PCR using TSG-6 primers.
Knockdown of TSG-6 in MSC-CM EXO-injected BPD mice
using TSG-6 neutralizing antibody (NAb)
Newborn pups were exposed to hyperoxia (> 95% oxy-
gen) from birth to PN4. At PN5, all animals were placed
in room air (RA) up to PN14, to allow for a period of re-
covery. To analyze if NAb against TSG-6 affects the
therapeutic properties of EXO, we administered TSG-6
NAb (A38.1.20, Santa Cruz Biotechnology, Dallas, TX,
USA, 5 μg/dose) intraperitoneally, 1 day before EXO 25
wks injections (i.e., at PN1 and PN3) and 1 day after the
second injection (i.e., at PN5). Isotype IgG (R&D Sys-
tems, Minneapolis, MN, USA, 5 μg/dose) was used as
control injections for the NAb groups and were adminis-
tered at PN 1, 3 and 5. The pups were kept at RA till
PN14 for echo analysis and harvesting the tissues for
other analysis.
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Statistical analysis
Statistical analyses were performed using one-way ana-
lysis of variance (ANOVA) followed by Tukey’s post hoc
test for comparison between three or more groups using
GraphPad Prism software 7.0 for Windows (GraphPad
Software, San Diego, CA, USA). Statistical significance
was defined as p < 0.05. Mean values were expressed as
mean ± SEM. The number of mice/group is indicated in
the legend of each figure.
Results
Isolated preterm hUCs MSC, but not fibroblast, injections
improve the BPD pulmonary phenotype
In initial experiments, we isolated MSCs from preterm
(32 weeks) hUCs and injected them in our mouse BPD
model. Human primary dermal fibroblast (HDF) cells ob-
tained from American Type Culture Collection (ATCC)
(Manassas, VA, USA) were also injected, as control cells,
in the BPD mice. HDF were grown as per instructions
provided with the cells. As shown in Additional file 1:
Figure S1, chord length, indicative of alveolar size, was in-
creased in the BPD mice, with no difference as compared
to the BPD mice injected with fibroblasts. On the other
hand, hUC MSC-injected BPD mice lungs showed an im-
provement in the pulmonary phenotype, as evidenced by
significant decrease in chord length value compared to the
other two BPD groups (Additional file 1: Figure S1).
Isolation of hUC MSCs and collection of UC-MSC CM and
EXO for injection into BPD mouse model
hUC MSCs were isolated and characterization of
UC-MSCs was performed as per the International Society
of Cell Therapy (ISCT) guidelines. The isolated WJ-MSCs
were adherent to plastic, displayed a fibroblast-like pheno-
type and showed unaltered viability (Additional file 1: Fig-
ure S2A). Characteristic cell surface markers of MSCs
were identified at passage 3 by flow cytometry. Cells were
positive for CD105, CD73 and CD90 and prominently
negative for hematopoietic stem cell markers HLA-DR,
CD19 and CD14 surface molecules as shown by standard
FACS (Additional file 1: Figure S2B). UC-MSCs were ex-
panded in culture up to passage 5 to study their growth
kinetics. There was no significant difference between
mean population doubling time for 25 and 30 wks GA UC
MSCs, ~ 33.5 h and ~ 35 h, respectively. On differenti-
ation, UC-MSCs differentiated into multilineage adipo-
cytes, osteocytes and chondrocytes as detected by staining
with Oil Red O, Alizarin S Red and Alcian Blue, respect-
ively (Additional file 1: Experimental procedures and Fig-
ure S2C).
To study whether the secretome of MSCs plays an im-
portant role in its therapeutic effects, we used CM and
EXO from UC MSCs as a feasible i.p. treatment in our
well-established murine hyperoxia-induced BPD model
[19, 20, 24, 26]. CM was collected from MSCs incubated
with SFM for 24 h at 37 °C in the CO2 incubator. Cul-
turing MSCs in SFM after washing the monolayer with
PBS allowed us to ensure that no exosomal contamin-
ation from the FBS is carried over to the MSC-CM col-
lected, and all EXO present in the CM, after 24 h
incubation, are those secreted from the MSCs. MSC-CM
was concentrated tenfold and was injected intraperitone-
ally into the BPD mouse model.
Isolation of EXO from the CM and its characterization
EXO were isolated from the CM by serial centrifugation
following modified Thery’s protocol [28] as described in
the Additional file 1: Experimental procedures. Isolated
EXO were characterized by electron microscopy (EM)
for morphology and size (Additional file 1: Figure S3A).
EM revealed a heterogeneous exosome population of
MSC-CM EXO, having a typical diameter of 40–
140 nm. Particle number administered in each dose as
analyzed by NTA particle number: 25 wks EXO 4.5 ×
108 particles, 30 wks EXO 2.88 × 107 particles. Represen-
tative plots of the 25 wks EXO and 30 wks EXO are
shown in Additional file 1: Figure S3B. The 25 wks EXO
and 30 wks EXO samples were diluted 1:50 and 1:20, re-
spectively, for the analysis. Dot blot was performed,
loading equal amounts of protein, to characterize iso-
lated EXO after probing with exosome-specific surface
marker, CD63. Trans-Golgi network protein (TGN48)
was used as a negative control for the EXO. CD63 was
expressed in the CM and EXO fractions of 25 and 30 wks
CM, demonstrating the presence of EXO in both CM and
EXO fractions (Additional file 1: Figure S3C). No signal
for TGN48 was detected in the EXO fraction of both 25
and 30 wks CM, though the signal was seen in the CM
depicting that the EXO fraction isolated is pure and does
not have cytoplasmic membranes (Additional file 1: Figure
S3D). No signal was detected for DMEM:F12 and PBS
fractions, which are devoid of any cells and cellular com-
partments. Western blotting detected characteristic exoso-
mal marker CD81 (25 kDa) in the EXO fraction of
MSC-CM, both at 25 wks and 30 wks (Additional file 1:
Figure S3E). Specific signal for the exosomal marker
Alix-1 (97 kDa) was also detected for 25 wks GA MSCs,
CM and EXO samples by Western blotting (Additional
file 1: Figure S3F). I.p. injections of MSC-CM EXO from
25 and 30 wks GA UC were done after protein concentra-
tion determination, as described in the Methods, to deter-
mine the effect of EXO in the BPD mouse model.
MSC secretome treatment reverses hyperoxia-induced
pulmonary inflammation and alveolar-capillary leak in the
BPD mouse model
To determine if hyperoxia-induced lung inflammation
responds to MSC paracrine signals, we performed i.p.
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injections of concentrated UC MSC-CM or UC MSC-CM
EXO into pups (at PN2 and PN4) exposed to hyperoxia
(> 95% O2). After 4 days hyperoxia exposure from birth to
PN4, these pups were placed at RA until PN14, as defined
in our hyperoxia-induced BPD mouse model (Fig. 1a) [19,
20, 24, 26]. The control group comprised of pups exposed
to the same hyperoxia conditions and injected with vehicle
(serum-free culture media-DMEM: F12 or PBS) at PN2
and PN4. Hyperoxia resulted in accumulation of inflam-
matory cells on injury, indicated by a statistically signifi-
cant increase in total cell count in BALF in BPD
compared to RA (Fig. 1b) mice. However, on MSC-CM or
EXO treatment, BALF total cell count was statistically de-
creased to RA levels (Fig. 1b). No significant decrease in
BALF total cell count was observed in BPD mice injected
with the vehicle (DMEM:F12 or PBS). Similarly, there was
a significant increase in infiltration of neutrophils, as
assessed by the absolute neutrophil count, in BALF of
BPD compared to RA. This increase in neutrophil count
in BPD mice was blocked on treatment with MSC-CM or
EXO 25 and 30 wks (Fig. 1c). No changes were noted in
the percentages of BALF macrophages (Additional file 1:
Figure S4A).
Hyperoxia-induced lung injury is characterized by endo-
thelial cell damage and disruption of the alveolar-capillary
barrier, leading to increased protein leak in the BALF. To
determine the extent of capillary leakage, the protein con-
centration in BALF was measured (Fig. 1d). There was a
statistically significant increase in BALF protein in BPD
versus RA mice. This increase in total BALF protein in
BPD was not diminished on treatment with DMEM:F12
or PBS; however, MSC-CM or EXO treatment signifi-
cantly decreased the protein leak. In summary, our results
show that MSC-CM and EXO treatment significantly sup-
pressed inflammatory cell accumulation in the lung and
has a protective role in the maintenance of the
alveolar-capillary barrier in the presence of hyperoxia.
MSC-CM or EXO treatment reverses alveolar injury, septal
thickness and other morphometric alterations associated
with hyperoxia-induced lung injury in the BPD mouse
model
Impaired alveolar growth, as evidenced by fewer and lar-
ger alveoli with heterogeneous sizes, was observed in BPD
compared to RA lungs. These impairments in alveolar
growth and morphological changes observed in BPD were
attenuated in the MSC-CM or EXO-injected pups but not
in DMEM:F12 or PBS-injected pups (Fig. 2a, b). Based on
morphometric analysis, the chord length, which is indica-
tive of alveolar size, was significantly higher in BPD as
compared to RA groups. This hyperoxia-induced increase
in mean chord length was significantly ameliorated by
UC-MSC-CM or EXO treatment (Fig. 2c).
There was a statistically significant increase in alveolar
septal thickness in BPD and DMEM:F12 or PBS-injected
group compared to RA (Fig. 2d). This increase in septal
thickness was significantly reduced to RA levels on ad-
ministration of MSC-CM or EXO, both in 25 and 30
wks groups, depicting the therapeutic effect of the secre-
tome (Fig. 2d). Alveolar area was significantly increased
in BPD compared to RA lungs. Injecting the BPD mice
with vehicle DMEM:F12 or PBS had no effect. However,
alveolar area was significantly reduced to the RA levels
after MSC-CM or EXO injections in BPD mice (Fig. 2e).
Further in-depth analysis of other lung morphological pa-
rameters, such as number of branches, junctions (Fig. 2f, g),
triple points and quadruple points (Additional file 1: Figure
S4B-C) was performed. Interestingly, we found that al-
though both 25 and 30 wks CM treatment attenuated the
morphological alterations in BPD mouse model, CM or
EXO treatment from earlier gestational age, 25 wks GA
UC showed statistically significant improvement in select-
ive lung morphometric parameters when compared to
CM or EXO from 30 wks GA UC (Fig. 2f, g, Additional
file 1: Figure S4B-C). To summarize, MSC-CM treatment
significantly improved pulmonary architecture in the
hyperoxia-induced mouse BPD model, with a preferential
enhanced response from the CM or EXO derived from
the 25 wks GA UC.
To further assess the mechanism of the improved archi-
tecture in lung tissue, we evaluated apoptosis using TUNEL
assay. Hyperoxia causes oxidant-induced DNA injury and
cell death that manifests as enhanced pulmonary tissue
TUNEL staining. Apoptotic cells were seen significantly
more in BPD compared to RA (Additional file 1: Figure
S4D). MSC-CM or EXO treatment significantly decreased
hyperoxia-induced cell death in the lungs of the BPD mice
(Additional file 1: Figures S4D-E and S5A-B). Similar de-
crease in cell death on treatment with MSC-CM EXO was
shown by cleaved caspase-3 staining (Additional file 1:
Figure S5C-D). We further demonstrate that MSC-CM
EXO treatment rescued hyperoxia-induced loss of periph-
eral pulmonary blood vessels in the BPD mice (Additional
file 1: Figure S6). The immunofluorescence intensity of
CD31 staining, a known marker of blood vessels, was sig-
nificantly reduced in BPD as compared to RA in PN14
pups. This hyperoxia-induced loss of CD31 staining was
significantly increased in the MSC-CM EXO-injected
groups (Additional file 1: Figure S6).
MSC secretome treatment reverses PH-induced RVH in
the BPD mouse model
PAAT values from different treatment conditions were
obtained by high-resolution echocardiography, as de-
scribed before [35]. PAAT, as a surrogate of mean PA
pressure, was found to be shortened in BPD animals and
vehicle-injected (DMEM:F12) BPD mice (Fig. 3aII-III)
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but reverted to RA levels in MSC-CM 30 wks-treated
BPD mice (Fig. 3a I, V, b). The ratio between PAAT and
PAET show significant decrease in BPD and DMEM:-
F12-injected groups as compared to RA. However, on
treatment with CM, there was significant increase in
PAAT/PAET ratio, indicative of reversal of PH (Fig. 3c).
RVH, as depicted by RV to LV ratio, was statistically
significantly increased in BPD when compared to RA.
RVH was attenuated on MSC-CM treatment (Fig. 3d).
Fulton’s index, calculated as [RV/(LV + IVS)], also deter-
mines RVH, was significantly increased in BPD pups as




Fig. 1 hUC MSC secretome treatment reverses pulmonary inflammation and alveolar-capillary leak associated with hyperoxia-induced lung injury
in the BPD mouse model. a Schematic representation of BPD mouse model and secretome injection regime. The mice were kept in 100%
oxygen from birth to PN4 followed by RA exposure till PN14. The mice were used for echocardiography and sacrificed for analysis at PN14. IP
injections of hUC MSC-CM or hUC MSC-CM EXO were given at PN2 and PN4. 10 μg of MSC-CM and 2.5 μg of MSC-CM EXO (GA 25 wks and 30
wks), resuspended in 100 μl of PBS respectively, was injected into each neonatal mouse at PN2 and PN4. b-d Histogram showing BALF total cell
count (b), BALF absolute neutrophil count (c), total BALF protein (d), in RA, BPD and vehicle (DMEM:F12 or PBS)-injected, MSC-CM or EXO 25 wks-
injected, MSC-CM or EXO 30 wks-injected BPD mice at PN14. All values are expressed as mean ± standard error of the mean (SEM); eight experiments,
N = 3–9 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BALF bronchoalveolar
lavage fluid, BPD bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, hUC human umbilical cord, i.p. intraperitoneal,
MSC mesenchymal stem cell, PBS phosphate-buffered saline, PN postnatal, RA room air
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MSC-CM significantly decreased the Fulton’s index to
RA levels (Fig. 3e). MSC-CM EXO 25 wks treatment sig-
nificantly increased the PAAT values of BPD mice to RA
levels (Fig. 3f, g). Treatment with EXO from both 25
wks and 30 wks UC MSCs significantly increased PAAT/
PAET ratio, indicative of reversal of PH. There was no
difference between the BPD and PBS-injected groups
depicting specific attenuation after MSC-CM EXO injec-
tions (Fig. 3h). We demonstrate that MSC-CM EXO
treatment attenuated RVH and PH, as depicted by sig-
nificantly decreased RV/LV ratio (Fig. 3i), and the Ful-
ton’s index (Fig. 3j) in BPD mice.
MSC secretome treatment show decreased hyperoxia-
induced cell death in the brain in the BPD mouse model
To evaluate apoptosis levels in brain tissue, the mouse
brain was divided into four different regions: olfactory






Fig. 2 hUC MSC secretome treatment reverses altered lung morphology associated with hyperoxia-induced lung injury in the BPD mouse model.
a Representative images of lung histology with H&E stain from the five experimental groups, RA (I), BPD (II), BPD + DMEM:F12 (III), BPD +MSC-CM
25 wks (IV), BPD + MSC-CM 30 wks (V). Asterisks depicts the increased alveolar simplification in the BPD and DMEM:F12-injected BPD mice as
compared to RA. ×200 magnification, Scale bar: 50 μm. b Representative images of lung histology with H&E stain from the five experimental
groups, RA (I), BPD (II), BPD + PBS (III), BPD + MSC-CM EXO 25 wks (IV), BPD +MSC-CM EXO 30 wks (V). Asterisks depict the increased alveolar
simplification in the BPD and PBS-injected BPD mice as compared to RA. ×200 magnification, Scale bar: 50 μm. c-g Histogram depicting the
mean chord length (c), septal thickness (d), alveolar area (e), number of branches (f), number of junctions (g) in lungs of RA, BPD, DMEM:F12 or
PBS-injected, MSC-CM or EXO 25 wks-injected, MSC-CM or EXO 30 wks-injected BPD mice at PN14. All values are expressed as mean ± standard
error of the mean (SEM); eight experiments, N = 3–7 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. BPD bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, MSC mesenchymal stem cell, PBS phosphate-buffered saline,
PN postnatal, RA room air
Chaubey et al. Stem Cell Research & Therapy  (2018) 9:173 Page 9 of 26
lateral ventricles), midbrain (comprising of corpus callo-
sum and hippocampus) and hindbrain (comprising of
cerebellum). TUNEL staining was performed in different
regions of the brain. No difference in cell death between
the RA, BPD, vehicle-injected (DMEM:F12 or PBS) and
MSC-CM or EXO-injected groups was detected in the
olfactory bulb region (Additional file 1: Figure S7A and
E). Apoptotic cells were significantly more in BPD com-
pared to RA in forebrain (Additional file 1: Figure S7B
and F). MSC-CM treatment significantly reduced fore-
brain cell apoptosis (Additional file 1: Figure S7B). Sta-








Fig. 3 hUC MSC secretome treatment reverses PH and RV hypertrophy in hyperoxia-induced lung injury. a Echocardiography shows reversal of
cardiac dysfunction on MSC-CM treatment in the BPD mouse model. The white line in the echocardiogram depicts PAAT values for the specific
group, where PAAT is the pulmonary artery acceleration time. b Graph demonstrating PAAT values from the five experimental groups at PN14.
c Graph depicting PAAT/PAET ratio where PAET is the pulmonary artery ejection time. d Histogram showing the RV to LV ratio in the five experimental
groups. e Fulton’s index [RV/(LV + IVS)], reflecting right ventricular hypertrophy, in the five experimental groups at PN14. f Echocardiography shows
reversal of cardiac dysfunction on MSC-CM EXO treatment in the BPD mouse model. The white line in the echocardiogram depicts PAAT values for the
specific group. g Graph demonstrating PAAT values from the five experimental groups at PN14. h Graph depicting PAAT/PAET ratio where PAET is the
pulmonary artery ejection time. i Histogram showing the RV to LV ratio in the five experimental groups. j Fulton’s index [RV/(LV + IVS)], reflecting right
ventricular hypertrophy, in the five experimental groups at PN14. All values are expressed as mean ± standard error of the mean (SEM); 5 experiments,
N = 3–7 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BPD bronchopulmonary
dysplasia, CM conditioned medium, EXO exosomes, IVS interventricular septa, LV left ventricular, MSC mesenchymal stem cell, PAAT pulmonary artery
acceleration time, PAET pulmonary artery ejection time, PBS phosphate-buffered saline, RA room air, RV right ventricular
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in midbrain and hindbrain regions of MSC-CM or
EXO-treated pups (Additional file 1: Figures S7 C-D and
G-H), demonstrating that UC-MSC CM or EXO differ-
entially attenuate cell death in brain, in different regions
of the brain. No recovery was observed in the BPD pups
injected with the vehicle injections (DMEM:F12 or PBS).
MSC CM EXO reverses hypomyelination and glial fibrillary
acidic protein (GFAP) expression in the brain of BPD mice
Myelin binding protein (MBP) is involved in develop-
ment of white matter in the brain and is a marker of ma-
ture oligodendrocytes. We assessed brain myelination by
immunofluorescent staining of corpus callosum region
of RA, BPD and MSC-CM EXO-treated BPD mice for
MBP at PN14 (Additional file 1: Figure S8A and C).
BPD mice injected with PBS were used as controls. MBP
mean pixel intensity, indicative of the extent of brain
myelination, was significantly reduced in BPD and
PBS-injected group compared to RA group (Additional
file 1: Figure S8A I-III). However, on MSC-CM EXO
treatment, MBP expression was significantly increased in
BPD mice, thus depicting reduced loss of myelination in
the brains of BPD mice (Additional file 1: Figure S8A
IV-V and C). We evaluated the effect of MSC-CM EXO
treatment on GFAP, a characteristic marker of astro-
cytes, levels in hippocampus of BPD brain at PN14. Im-
munofluorescent staining of the brain sections with
GFAP show statistically significantly decreased mean
pixel intensity in BPD compared to RA (Additional file
1: Figure S8 B I-II and D). However, on MSC-CM EXO
treatment, mean pixel intensity of GFAP in BPD mice
was significantly increased, suggesting an increase in as-
trocytes in the brains of treated BPD mice (Additional
file 1: Figure S8 B IV, V and D).
Therapeutic factor of UC-MSC secretome resides in the
EXO fraction
MSC-CM comprises secretome of the MSCs, which in-
cludes EXO. Both MSC-CM and MSC-CM EXO fractions
show improvement in BPD pathology on i.p. injections in
the neonatal BPD mouse model. To determine if EXO is
the therapeutic fraction of the secretome, we performed i.p.
injections of concentrated EXO-depleted MSC-CM 25 wks
into pups exposed to > 95% O2 in our hyperoxia-induced
BPD mouse model (Fig. 4). The control group comprised
of BPD pups injected with vehicle (serum-free culture
media-DMEM:F12). We chose the 25 wks GA MSC-CM
samples to deplete the EXO as the recovery was augmented
with this early GA. To obtain EXO-depleted fraction, we
utilized the CM supernatant obtained after pelleting down
MSC-CM EXO 25 wks, during EXO isolation by ultracen-
trifugation. The EXO-depleted MSC-CM 25 wks obtained
was tenfold concentrated to prepare for the injection re-
gime (Fig. 4).
EXO-depleted MSC-CM 25 wks treatment had no ef-
fect on the hyperoxia-induced pulmonary inflammation
and alveolar-capillary leak in the BPD mouse model.
BALF total cell count (Fig. 4a), BALF absolute neutro-
phil counts (Fig. 4b) and total BALF protein concentra-
tion (Fig. 4c) were significantly high in EXO-depleted
MSC-CM 25 wks-injected groups as compared to RA.
EXO-depleted MSC-CM 25 wks-injected group showed
no reversal in the morphometric alterations in the
hyperoxia-induced lung injury (Fig. 4d-f and Additional
file 1: Figure S9A-D). The mean chord length, septal
thickness and alveolar areas were significantly higher in
EXO-depleted MSC-CM 25 wks-injected groups com-
pared to RA (Fig. 4d-f ). Other lung morphometric pa-
rameters such as number of branches, junctions, triple
points, quadruple points showed significant decrease in
EXO-depleted MSC-CM 25 wks fraction, similar to that
seen in the BPD and DMEM:F12-injected groups, when
compared to RA (Additional file 1: Figure S9).
EXO-depleted MSC-CM 25 wks injections did not res-
cue the PH and RVH associated with hyperoxia-induced
BPD. The ratio between PAAT and PAET show signifi-
cant decrease in BPD, DMEM:F12 and EXO-depleted
MSC-CM 25 wks-injected groups as compared to RA,
indicative of PAH (Fig. 4g). RV to LV ratio, indicative
of RVH, was statistically significantly increased in
BPD, DMEM:F12 and EXO-depleted MSC-CM 25
wks-injected groups as compared to RA (Fig. 4h). The
data set of MSC-CM 25 wks injected in BPD mice,
used earlier in this study, has been shown for compari-
son. Thus, we demonstrate that EXO-depleted
MSC-CM 25 wks does not reverse hyperoxia-induced
lung alterations and PH and RVH associated with
hyperoxia-induced BPD, suggesting that the thera-
peutic action of MSC-CM resides in the EXO fraction.
Human BPD tracheal aspirate and lung tissue of the BPD
mouse model demonstrate elevated TSG-6
Our results demonstrate that administration of
UC-MSC-CM EXO attenuates BPD pathology in lungs,
heart and brain. To determine which factors in EXO are
responsible for the recovery, we tested MSC-CM EXO
25 wks for the presence of an important immunomodu-
latory molecule, tumor necrosis factor α stimulated
gene-6 (TSG-6). The anti-inflammatory activity has been
directly demonstrated in a number of rodent models of
inflammation including models of arthritis [36, 37],
myocardial infarction [38], chemical injury to the cornea
[39] and peritonitis [40]. We analyzed the TSG-6 RNA
expression levels in human tracheal aspirates in patients
who developed BPD and demonstrated significantly ele-
vated levels as compared to non-BPD group (Additional
file 1: Figure S10A). This clinical result corresponds to
our mouse lung data, which demonstrates an increase in
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TSG-6 protein expression under pathological conditions
in lung tissue of BPD mice as a protective response to
increased inflammation (Additional file 1: Figure S10B).
We found by Western blotting and its densitometric
analysis that TSG-6 levels significantly increased in BPD
and PBS-injected BPD mice lung tissues compared to
RA (Additional file 1: Figure S10B). However, on admin-
istration of MSC-CM EXO in BPD mice, TSG-6 levels in
their lungs decreased to that of RA levels. No statisti-
cally significant difference was seen in TSG-6 levels be-
tween BPD mice and BPD mice injected with vehicle
PBS, thus suggesting that the increase in TSG-6 expres-
sion in BPD or PBS-injected BPD mice may be
associated with inflammatory response for protection
against hyperoxia-induced lung injury (Additional file 1:
Figure S10B).
TSG-6 detected in EXO fraction of MSC-CM 25 wks
protects against pulmonary inflammation and reverses
morphometric alterations associated with hyperoxia-
induced lung injury
Western blotting was performed to check for the pres-
ence of TSG-6 in 25 wks GA MSCs, CM and EXO
(Additional file 1: Figure S10C). Vehicle controls -




Fig. 4 EXO-depleted MSC-CM 25 wks injections does not reverse hyperoxia-induced pulmonary inflammation, altered morphology, PH and RVH
in the BPD mouse brain. a-c Histograms showing BALF total cell count (a), BALF absolute neutrophil count (b), total BALF protein (c) in RA, BPD,
DMEM:F12-injected, MSC-CM 25 wks and EXO-depleted MSC-CM 25 wks-injected BPD mice at PN14. d-f Histograms showing the mean chord
length (d), septal thickness (e), alveolar area (f) in lungs of RA, BPD, DMEM:F12-injected, MSC-CM 25 wks and EXO-depleted MSC-CM 25 wks-
injected BPD mice. g-h Graph demonstrating PAAT/PAET ratio (g), RV to LV ratio (h), reflecting RV hypertrophy, in the five experimental groups at
PN14. MSC-CM 25 wks data set used earlier in this manuscript was used for comparison with the EXO- depleted MSC-CM 25 wks group. All values
are expressed as mean ± SEM; five experiments, N = 3–9 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. BPD bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, LV left ventricular, MSC mesenchymal stem
cell, PAAT pulmonary artery acceleration time, PAET pulmonary artery ejection time, PBS phosphate-buffered saline, RA room air, RV right ventricular
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signal at ~ 37 kDa (the size of TSG-6) was detected in
25 wks CM and EXO fractions (Additional file 1: Figure
S10C). No signal was detected for DMEM:F12 and PBS
fractions, which are devoid of any cells and cellular com-
partments, thus depicting presence of TSG-6 in the
EXO fraction of MSC-CM 25 wks.
To investigate whether TSG-6, detected in MSC-CM
EXO 25 wks, acts as one of the mediators in attenuation
of BPD pathology, we injected recombinant human (rh)
TSG-6 intraperitoneally in the BPD mouse model and
studied its therapeutic effects. Administration of TSG-6
protein in BPD mice at PN2 and PN4 (Fig. 5a) signifi-
cantly decreased the total cell count (Fig. 5b), infiltration
of neutrophils (Fig. 5c) and protein leak (Fig. 5d) in the
BALF of the TSG-6-injected group versus BPD, thus dem-
onstrating decreased hyperoxia-induced alveolar-capillary
leakage and preserved alveolar-capillary barrier in the
lung.
The increase in mean chord length and septal thick-
ness found in BPD was significantly ameliorated by
TSG-6 treatment (Fig. 5e-g), depicting the therapeutic
effect of TSG-6. Significant increase in alveolar area, ob-
served in BPD group, was significantly reduced after
TSG-6 injections in BPD mice (Fig. 5h). Interestingly,
on TSG-6 administration, other lung morphological
parameters like number of branches, junctions, junc-
tion voxels (Fig. 5i-k), triple points and quadruple
points (Additional file 1: Figure S11A, B) showed sta-
tistically significant improvement in BPD mice. To
summarize, TSG-6 treatment significantly improved
pulmonary architecture in the BPD model, suggesting
an important role of TSG-6 as a therapeutic molecule
in hyperoxia-induced lung injury.
We also demonstrate that TSG-6 decreased the loss of
peripheral pulmonary blood vessels in the BPD mouse
(Additional file 1: Figure S11C, D). The immunofluores-
cence intensity of CD31 was significantly reduced in BPD,
which reverted back to RA levels in TSG-6-injected
groups, thus demonstrating decreased loss of peripheral
blood vessels after TSG-6 administration.
TSG-6 reverses BPD-associated cardiac and brain
pathologies in the BPD mouse model
PAAT/PAET values were significantly decreased in the
BPD and PBS-injected groups, as compared to RA.
However, treatment with TSG-6 significantly increased
PAAT/PAET ratio, indicative of reversal of PH. No dif-
ference between the BPD and PBS-injected groups was
observed, depicting specific attenuation after TSG-6 in-
jections (Fig. 6a-c). RV/LV ratio was significantly in-
creased and Fulton’s index in BPD mice was significantly
decreased on TSG-6 treatment (Fig. 6d-e), depicting a
reversal of RVH.
TUNEL assay demonstrated no significant difference
in cell death in the olfactory bulb region between RA,
BPD, PBS (vehicle)-injected and TSG-6 groups
(Additional file 1: Figure S12A). However, TSG-6
treatment reduced cell apoptosis in forebrain and
hindbrain (Additional file 1: Figure S12B, D). We
found a trend towards decreased cell death in the
TSG-6-injected versus PBS-injected group in forebrain
and hind brain, which was not significant. We show
statistically significant decrease in cell death in mid-
brain of TSG-6-treated pups (Additional file 1: Figure
S12C), demonstrating that TSG-6 differentially attenu-
ates cell death in the midbrain of BPD mice.
TSG-6 administration significantly increased MBP and
GFAP expression in BPD brain (corpus callosum and
hippocampus regions, respectively) (Additional file 1:
Figure S12E-H), compared to BPD or PBS-injected
groups, suggesting a dcrease in myelin loss and an in-
crease in astrocyte formation.
TSG-6 treatment decreases proinflammatory cytokines IL-
6, TNF-α and IL-1β and cell death in lungs of the BPD
mouse model
IL-6, a proinflammatory cytokine, has been shown to be
elevated in different lung diseases [41]. Hyperoxia in-
creases levels of IL-6 and causes increased lung cell
death in newborn mice [20]. ELISA was performed to
determine whether MSC-CM EXO treatment or TSG-6
administration decreases the levels of proinflammatory
cytokine IL-6 in the lungs of BPD mice. We demonstrate
that IL-6 levels were decreased in lung after MSC-CM
EXO 25 wks/30 wks or TSG-6 treatment, indicating a
decreased proinflammatory response (Fig. 7a-b). We
demonstrate that the increased expression of IL-6 and
other proinflammatory cytokines, such as TNF-α and
IL-6, in BPD groups were significantly attenuated on
treatment with MSC-CM EXO 25 and TSG-6 (Fig. 7c-e)
as shown by real-time PCR.
We demonstrate that TSG-6 administration also de-
creased hyperoxia-induced cell death in the lungs in the
BPD mouse. Percentage of TUNEL-positive dead cells
were significantly increased in BPD, which reverted back
to RA levels in TSG-6-injected groups (Fig. 7f-g). De-
crease in cell death in the BPD lung on TSG-6 adminis-
tration suggests that TSG-6 may partly prevent the lung
injury induced by BPD in neonatal mice, probably via
modulating the expressions of proinflammatory cyto-
kines like IL-6, TNF-α and IL-1β in the lung tissue.
Knockdown of TSG-6 in MSC-CM EXO significantly
decreases therapeutic effects of MSC-CM EXO
To analyze the role of TSG-6 as a therapeutic mediator,
loss of the function of TSG-6 was performed by TSG-6
knockdown using TSG-6 neutralizing antibodies (NAb)
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or TSG-6 siRNA. Intraperitoneal injection of TSG-6
NAb was performed in BPD mice, spaced between
MSC-CM EXO 25 wks injections, at PN1, PN3 and
PN5. MSC-CM EXO 25 wks was administered at PN2
and PN4. Pups were transferred to RA from PN4 to
PN14 followed by echocardiography and collection of
tissue for the study. Administration of TSG-6 NAb in






Fig. 5 TSG-6 reverses hyperoxia-induced pulmonary inflammation and altered morphology in the BPD mice. a Schematic representation of BPD
mouse model and TSG-6 injection regime. 5 μg of rhTSG-6 resuspended in total 100 μl of PBS was injected into each neonatal mouse at PN2 and
PN4. b-d Histograms showing BALF total cell count (b), BALF absolute neutrophil count (c), total BALF protein (d) in RA, BPD, PBS-injected and
TSG-6-injected BPD mice at PN14. e Representative images of lung histology with H&E stain from the four experimental groups, RA (I), BPD (II),
BPD + PBS (III), BPD + TSG-6 (IV). Asterisks depict the increased alveolar simplification in the BPD and PBS-injected BPD mice as compared to RA.
×200 magnification, Scale bar: 50 μm. f-k Histograms showing the mean chord length (f), septal thickness (g), alveolar area (h), number of
branches (i), junctions (j), junction voxels (k) in lungs of RA, BPD, PBS-injected, TSG-6-injected BPD mice. All values are expressed as mean ± SEM;
four experiments, N = 3–8 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
BALF bronchoalveolar lavage fluid, BPD bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, i.p. intraperitoneal, MSC mesenchymal
stem cell, PAAT pulmonary artery acceleration time, PAET pulmonary artery ejection time, PBS phosphate-buffered saline, PN postnatal, RA room air,
TSG-6 tumor necrosis factor alpha-stimulated gene-6
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infiltration of neutrophils (Fig. 8b) and protein leak (Fig.
8c) in the BALF of TSG-6 NAb-injected group versus
RA or Isotype IgG control, thus demonstrating increased
hyperoxia-induced alveolar-capillary leakage and disrupted
alveolar-capillary barrier in the lung. There was no change
in the percentages of BALF macrophages among different
groups in NAb TSG-6 EXO 25wks-injected BPD mice
(Additional file 1: Figure S13A). The mean chord length
and alveolar area (Fig. 8d-f) was comparable to that of
BPD and significantly more than RA, depicting significant
hyperoxia-induced damage even after EXO treatment.
PAAT values were significantly decreased in the BPD and
PBS-injected groups, as compared to RA. There was no
significant difference between RA and MSC-CM EXO 25
wks-treated BPD mice. However, treatment with NAb
TSG-6 + EXO 25 wks significantly decreased PAAT value,
indicative of PH. No difference between BPD and NAb
TSG-6 -injected groups was observed (Additional file 1:
Figure S13B). RV/LV ratio and Fulton’s index was signifi-




Fig. 6 TSG-6 treatment corrects PH and RVH and attenuates hypomyelination and GFAP decrease in BPD mouse brain. a Echocardiography
shows reversal of cardiac dysfunction on TSG-6 treatment in the BPD mouse model. The white line in the echocardiogram depicts PAAT values for
specific group. b Graph demonstrating PAAT values from the four experimental groups at PN14. c Graph depicting PAAT/PAET ratio from the four
experimental groups at PN14. d Histogram showing the RV to LV ratio in the four experimental groups. e Fulton’s index, [RV/(LV + IVS)], reflecting
RV hypertrophy, in the four experimental groups at PN14. All values are expressed as mean ± SEM; four experiments, N = 3–8 mice per group;
one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BALF bronchoalveolar lavage fluid, BPD
bronchopulmonary dysplasia, CM conditioned medium, IVS interventricular septa, LV left ventricular, PBS phosphate-buffered saline, RA room air,
RV right ventricular, TSG-6 tumor necrosis factor alpha-stimulated gene-6





Fig. 7 TSG-6 treatment decreases proinflammatory cytokines and cell death in lungs of the BPD mouse model. a IL-6 levels measured using
ELISA in lung tissue of RA, BPD, MSC-CM EXO 25 wks- and MSC-CM EXO 30 wks-injected BPD mice at PN14. b IL-6 levels measured using ELISA in
lung tissue of RA, BPD and TSG-6-injected BPD mice at PN14. c-e Pro-inflammatory cytokines levels in the lung tissues of RA, BPD and BPD mice
injected with PBS, MSC-CM EXO 25 wks and TSG-6. Histogram showing relative expression of IL-6 (c), TNF-α (d) and IL-1β (e) as determined using
real-time PCR. f Representative TUNEL immunofluorescence images of lung from the four experimental groups, RA (I), BPD (II), BPD + PBS (III), BPD
+ TSG-6 (IV). TUNEL-positive cells are labeled with FITC (green). The nuclei are counterstained with DAPI. Arrows depict TUNEL-positive dead cells
in the field. Scale bar: 50 μm. (g) Histogram depicting the quantitative analysis of TUNEL-positive cells in the lungs of RA, BPD, PBS-injected and
TSG-6-injected BPD mice. TUNEL-positive cells are expressed as a percentage, as described in Additional file 1: Methods. All values are expressed
as mean ± SEM; 3–4 experiments, N = 3–5 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. BPD bronchopulmonary dysplasia, CM conditioned medium, DAPI 4,6-diamidino-2-phenylindole, EXO exosomes, IL-6 interleukin-6,
IL-1β interleukin 1 beta, MSC mesenchymal stem cell, PBS phosphate-buffered saline, RA room air, TNF-α tumor necrosis factor alpha, TSG-6 tumor
necrosis factor alpha-stimulated gene-6, TUNEL terminal deoxynucleotidyl transferase dUTP nick-end labeling





Fig. 8 Administration of TSG-6 neutralizing antibody abrogates the therapeutic effects of MSC-CM EXO 25 wks. a-c Histogram showing BALF total
cell count (a), BALF absolute neutrophil count (b), total BALF protein (c), in RA, BPD and PBS-injected, MSC-CM EXO 25 wks-injected, Isotype IgG
+ EXO 25 wks and NAb TSG-6 + EXO 25 wks-injected BPD mice at PN14. d Representative images of lung histology (H&E staining) from the six
experimental groups, RA (I), BPD (II), BPD + PBS (III), BPD + MSC-CM EXO 25 wks (IV), BPD + Isotype IgG + EXO 25 wks (V), BPD + NAb TSG-6 + EXO
25 wks (VI). Asterisks depict the increased alveolar simplification in the BPD, PBS and NAb TSG-6 + EXO-injected BPD mice as compared to RA.
×200 magnification, Scale bar: 50 μm. e-f Histograms showing the mean chord length (e), alveolar area (f) in lungs of RA, BPD, PBS-injected,
Isotype IgG + EXO 25 wks- injected and NAb TSG-6 + EXO 25 wks-injected BPD mice. g-h Histogram showing the RV to LV ratio (g) and Fulton’s
index [RV/(LV + IVS)] (h), reflecting right ventricular hypertrophy at PN14. 5 μg of NAb resuspended in total 100 μl of PBS was injected into the
neonatal mice at PN2 and PN4. RA, BPD, BPD + PBS and BPD +MSC-CM EXO 25 wks samples used for comparison in this analysis are from Figs. 1,
2 and 3. All values are expressed as mean ± SEM; six experiments, N = 3–8 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BALF bronchoalveolar lavage fluid, BPD bronchopulmonary dysplasia, CM conditioned medium, EXO
exosomes, IVS interventricular septa, LV left ventricular, MSC mesenchymal stem cell, NAb neutralizing antibody, PBS phosphate-buffered saline, RA
room air, RV right ventricular, TSG-6 tumor necrosis factor alpha-stimulated gene-6
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(Fig. 8g-h), depicting BPD pathology of the heart. The
control Isotype IgG group was not statistically different
from the RA group, but there was a statistically signifi-
cant difference between the Isotype IgG control group
or MSC-CM EXO 25 wks and NAb TSG-6 + EXO 25
wks group, thus demonstrating a specific decrease in
the therapeutic effects of the EXO on TSG-6
knockdown.
Twenty-five weeks GA MSCs were transfected with
TSG-6 siRNA, and TSG-6 knockdown efficiency was cal-
culated. We obtained 70–75% knockdown of TSG-6 in
MSCs, when compared to the control group comprising
MSCs transfected with scr siRNA (Additional file 1: Figure
S13C-D). EXO was isolated from TSG-6siRNA-transfected
MSC-CM and injected in the mouse model of BPD to
analyze the effect of TSG-6 siRNA EXO 25 wks on differ-
ent BPD parameters.
Administration of TSG-6 siRNA EXO 25 wks into
BPD mouse significantly increased the total cell count
(Fig. 9a), absolute neutrophil counts (Fig. 9b) and pro-
tein leak (Fig. 9c) in the BALF of TSG-6 siRNA EXO
25 wks-injected group versus RA or scr siRNA control.
There was no change in the percentages of BALF mac-
rophages among different groups in TSG-6 siRNA EXO
25 wks-injected BPD mice (Additional file 1: Figure
S13E). The mean chord length and alveolar area (Fig.
9d-f ) was comparable to that of BPD and significantly
more than RA, depicting significant hyperoxia-induced
damage. PAAT values were significantly decreased in
the BPD and PBS-injected groups, as compared to RA.
There was no significant difference between RA and
MSC-CM EXO 25 wks-treated BPD mice. However,
treatment with TSG-6 siRNA EXO 25 wks significantly
decreased PAAT value, indicative of PH. No difference
between BPD and TSG-6 injected groups was observed
(Additional file 1: Figure S13F). RV/LV ratio and Ful-
ton’s index was significantly increased on TSG-6 siRNA
EXO 25 wks treatment (Fig. 9g-h), depicting BPD path-
ology of the heart. The control scr siRNA EXO 25 wks
group was not statistically different from the RA group,
but there was a statistically significant difference be-
tween the scr siRNA control group or MSC-CM EXO
25 wks and TSG-6 siRNA EXO 25 wks group, thus
demonstrating specific loss in the therapeutic effects of
the EXO on TSG-6 knockdown. Thus, we see that
knockdown or silencing of TSG-6 in the administered
MSC-CM EXO results in loss of therapeutic activity,
whereas administering exogenous TSG-6 rescues the
therapeutic activity. To summarize, our results demon-
strates that the therapeutic effects of the secretome of
UC MSCs resides in the EXO fraction, and specifically,
TSG-6 is one of the mediators in the 25 wks GA
MSC-CM EXO, responsible for the attenuation of BPD
pathology (Fig. 10).
Discussion
Determining the most appropriate cell type and tissue
source is crucial for successful clinical translation of
cell-based therapies for protection against BPD. UC-WJ
represents an ethically non-controversial, clinically rele-
vant and easily accessible source of potent stem cells [42].
MSCs derived from UC exhibit biological advantages over
adult adipose tissue-derived or bone marrow-derived
MSCs, showing low immunogenicity, higher proliferative
capacity, increased secretion of chemokines, proinflamma-
tory proteins and growth factors and better neuroprotec-
tion efficacy [43–46]. Several lines of evidence suggest
that the therapeutic action of MSCs is due to its paracrine
effect rather than through cell replacement [47–49]. Dif-
ferent sources of secretome have been used including
bone marrow-derived MSCs [10] in contrast to our source
of secretome isolated from preterm UC-MSCs WJ. How-
ever, not much is known about the efficacy of preterm
MSC secretome and its paracrine factors in the treatment
of BPD at a developmentally appropriate window. Several
animal models have been developed and refined, repre-
senting the pathological pulmonary characteristics of the
lungs of human neonates with BPD. The mouse model of
BPD is most common due to relatively short gestational
age, allowing studies on different developmental stages of
lung. The saccular stage of murine lung development oc-
curs between E17 and PN4, therefore, full-term mouse
represents a developmental stage resembling that of a hu-
man preterm neonate between 24 and 28 weeks. Our re-
sults are described in the context of the experimental
model we used [19, 20, 22–26], where we show the model
of severe BPD (oxygen exposure in the saccular stage,
from birth till PN4) as compared to the models of
hyperoxia-induced acute lung injury (HALI), where ex-
posure to 60–100% oxygen is up to 2–4 weeks in mouse,
throughout saccular and alveolar stages [29], which corre-
sponds to the developmental stages extending from pre-
term to adolescence in humans. These are important
factors when assessing translational significance, as mod-
eling needs to be developmentally appropriate to mimic
human BPD as closely as possible [19 16]. Additionally, al-
though full-term mouse lungs, in the saccular stage, are
competent for proper gas exchange, human preterm neo-
nates often require supplemental oxygen and surfactant
administration. The model used in this study could repre-
sent a human preterm neonate who has been adequately
administered prenatal steroids (which results in lung mat-
uration) and is exposed to a high concentration of supple-
mental oxygen [21].
As higher number of circulating CD34+ hematopoietic
stem and progenitor cells have been reported in ex-
tremely preterm neonates compared to the full-term ne-
onates [18], we chose to isolate MSCs from 25 and 30
wks GA UC to see whether CM or EXO from earlier





Fig. 9 Administration of EXO isolated from TSG-6 siRNA knockdown MSCs did not suppress hyperoxia-induced inflammation and associated BPD
pathology. a-c Histogram showing BALF total cell count (a), BALF absolute neutrophil count (b), total BALF protein (c), in RA, BPD and PBS-
injected, MSC-CM EXO 25 wks-injected, scr siRNA EXO 25 wks and TSG-6 siRNA EXO 25 wks-injected BPD mice at PN14. d Representative images
of lung histology (H&E staining) from the six experimental groups, RA (I), BPD (II), BPD + PBS (III), BPD + MSC-CM EXO 25 wks (IV), BPD + scr siRNA
EXO 25 wks (V), BPD + TSG-6 siRNA EXO 25 wks (VI). Asterisks depict the increased alveolar simplification in the BPD, PBS and TSG-6 siRNA EXO 25
wks-injected BPD mice as compared to RA. ×200 magnification, Scale bar: 50 μm. e-f Histograms showing the mean chord length (e), alveolar
area (f) in lungs of RA, BPD, PBS-injected, scr siRNA EXO 25 wks-injected and TSG-6 siRNA EXO 25 wks-injected BPD mice. g-h Histogram showing
the RV to LV ratio (g) and Fulton’s index [RV/(LV + IVS)] (h), reflecting right ventricular hypertrophy at PN14. RA, BPD, BPD + PBS and BPD +MSC-
CM EXO 25 wks samples used for comparison in this analysis are from Figs. 1, 2 and 3. All values are expressed as mean ± SEM; six experiments, N = 3–
8 mice per group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BALF bronchoalveolar lavage
fluid, BPD bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, IVS interventricular septa, LV left ventricular, MSC mesenchymal stem
cell, PBS phosphate-buffered saline, RA room air, RV right ventricular, scr siRNA scrambled small interfering ribonucleic acid, TSG-6 tumor necrosis factor
alpha-stimulated gene-6
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GA MSCs demonstrate therapeutic effects on BPD path-
ology. We demonstrate that MSC-CM or EXO from
both 25 and 30 wks GA UC attenuated BPD pathology
even after the injury has commenced. Detailed lung
morphometric analyses reveal that MSC-CM or EXO
from 25 wks GA UC had statistically significant im-
provement in some parameters of BPD lung morphology
compared to 30 wks GA UC. This effect was more pro-
nounced in EXO fractions. This study demonstrates for
the first time that MSC-CM or EXO from earlier GA
UC is a suitable source for cell-free therapy for BPD. To
our knowledge, this is the first quantitative assessment
of effects of preterm UC-MSC-CM and EXO in vivo in
terms of BPD pathology in multiple organs including
lung, heart and brain. We chose early time points for
intervention, which corresponds to the early phase of in-
flammation, suggested to be the best anti-oxidative and
therapeutic time window of stem cell transplantation in
BPD [50, 51]. As only limited volume can be injected in
the neonatal pups, we concentrated the therapeutic
paracrine mediators in the secretome before administra-
tion. For injections, the CM was concentrated tenfold.
Our results demonstrate that the extent of correction
and survival in a BPD model using EXO fraction is
equivalent to that of a CM fraction isolated from the
UC-MSCs. CM and EXO fractions were obtained from
MSCs which were grown in SFM for 24 h, after washing
the monolayer with PBS, to ensure complete elimination
of FBS contamination in the collected CM or EXO.
Our previous study demonstrates that preterm hUC
MSC act as a potential therapeutic agent via paracrine
mechanism [52]; however, no significant therapeutic ef-
fect was observed when human dermal fibroblasts
(HDF-control cells) were injected in our BPD model.
Interestingly, Kourembanas’ group have also reported no
protection after injection with control cells, HDF or
HDF-EXO in the BPD mouse, thus showing the specifi-
city of the MSCs and its EXO for therapeutic use [17].
We demonstrate that DMEM:F12/PBS control injections
do not have any significant protective effect in BPD
mice. Earlier studies on long-term (6 months) assess-
ment of MSC-CM therapy show no adverse lung effects
on lung function and structure, when MSC-CM was
injected in RA control animals, thus showing that the
CM is safe to use for BPD therapy [53]. WJMSC-EXO
administration had no effect on non-injured lungs as
measured by mean linear intercept of RA mice and RA
mice treated with WJMSC-EXO [17]. Kourembanas’
group had previously found that EXO-depleted CM had
no effect in their animal model of BPD [29]. Further-
more, we demonstrate that EXO-depleted MSC-CM 25
wks, when injected in our BPD mouse model, does not
Fig. 10 Schematic representation of MSC-CM/EXO/TSG-6 treatment regimen and outcomes in the mouse model of BPD. BPD pathology is reversed
in the pups injected with secretome of hUC-derived MSCs. This therapeutic effect is mediated, at least in part, by exosomal factor TSG-6. BPD
bronchopulmonary dysplasia, CM conditioned medium, EXO exosomes, hUC human umbilical cord, i.p. intraperitoneal, MSC mesenchymal
stem cell, PN postnatal, TSG-6 tumor necrosis factor alpha-stimulated gene-6
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have any protective effects, establishing that the protect-
ive factors are present in the EXO fraction.
Secreted EXO are an attractive and quite plausible
means for MSCs to regulate multiple pathways and pro-
duce a robust therapeutic effect in vivo [54–56]. These
packaging vesicles in the MSC-CM, compared with cells,
are less immunogenic, more stable and can be stored
frozen with no loss of activity, and have no risk of aneu-
ploidy following in vivo allogeneic administration. EXO
can cross the blood–brain barrier, making them particu-
larly attractive as a new tool therapies for neurodegener-
ative diseases. Delivering EXO into the CNS using
intravenous, or intranasal, or intraperitoneal routes
avoids the need for neurosurgical interventions [57].
TSG-6, a 35–39 kDa-secreted anti-inflammatory pro-
tein produced by many cell types in response to inflam-
matory mediators like TNF-α and IL-1β, is one of the
key factors in the immunosuppressive properties of
MSCs [38–40, 58]. Microarray analysis show TSG-6 as
one of the most highly upregulated transcripts in
lung-lodged transplanted MSCs [38]. Previous studies
report that TSG-6, via binding to CD44, induces a
phenotypic shift in macrophages from proinflammatory
M1 to anti-inflammatory M2 type that protects the mice
against lung inflammation and injury induced by endo-
toxin lipopolysaccharide (LPS) [32, 59]. TSG-6 can play
a role by inhibiting components in the inflammation
network of proteases [58], suppressing neutrophil migra-
tion into the site of inflammation [60]. RNA sequencing
and its gene ontology show that there are 41 genes spe-
cifically induced by WJMSC-EXO treatment, few of
them are likely associated with extracellular matrix and
structural organization [17]. TSG-6 binds to hyaluronan
(HA) that is essential for stabilizing and remodeling the
extracellular matrix (ECM) during ovulation and inflam-
matory disease processes such as arthritis [61]. MSCs
seem to have relevant neuroprotective properties in ex-
perimental injury models of the brain [62, 63], which is
suggested to be mediated by TSG-6. An earlier study,
based on antibody protein array and ELISA, to examine
protein levels of cytokines released by MSC-CM under
serum-starved conditions show that the TSG-6 levels in-
creased dramatically [64]. Based on above observations,
we chose to analyze TSG-6 in the EXO fraction as one
of the mediators of therapeutic actions of MSC-CM.
TSG-6 is detected in a physiological and patho-
logical context associated with inflammation and tis-
sue remodeling [36, 65]. We report high levels of TSG-6 in
the lungs of BPD mouse, suggesting that BPD is associated
with elevated levels of TSG-6. This increase in TSG-6
levels could be a temporal and developmental-specific pro-
tective response. We detected TSG-6 protein in the CM
and in EXO fractions of 25 wks GA UC indicating that
TSG-6 is secreted by MSCs and TSG-6 by itself or in
combination with other mediators could yield new thera-
peutic options. We demonstrate that i.p. administration of
hUC-MSC secretome significantly attenuates neonatal
hyperoxia-induced BPD pathology, in part, via the
secretome-associated factor TSG-6.
TSG-6 is an immunomodulatory molecule, which has
been shown to be increased in pathological conditions in
response to increased inflammation. We report that TSG-6
levels are highly elevated in the lungs of BPD mouse
model, suggesting that BPD is associated with elevated
levels of TSG-6. An earlier study, based on antibody pro-
tein array and ELISA, to examine protein levels of cytokine
released by MSC-CM under serum-starved conditions
show that the releasing of TSG-6 increased most dramatic-
ally [64]. In this study, we also found that TSG-6 is re-
quired for protection against hyperoxia-induced injury in
lungs, heart and brain. Therefore, we hypothesize that the
observed elevated TSG-6 levels in lungs during
hyperoxia-induced lung injury could be a temporal and
developmental-specific response from the cells as a defense
mechanism or protection against the hyperoxia-induced
inflammatory conditions. This suggests that TSG-6 is part
of a negative feedback loop in the inflammatory response.
Physiologically, it appears that one of the functions of
TSG-6 is to counteract the inflammatory effects of TNF-a
and IL-1 [66]. Silencing of TSG-6 in the administered
MSCs resulted in loss of therapeutic activity, whereas, ad-
ministration of exogenous TSG-6 resulted in replication of
therapeutic activity, thus showing that the reduction in
TSG-6 in EXO-injected BPD mice show improvement in
the inflammatory status of the BPD mice.
Another possibility is that the elevated TSG-6 in BPD
(a pathological condition) is because of enhanced inflam-
mation reaching its threshold to the therapeutic level
once the MSC-CM/EXO treatment is done. Once it
reaches this level, TSG-6 level decreases due to a nega-
tive feedback response. This concept of “sufficiency”
(reaching a maximal level to generate a “protective” re-
sponse) and enhancement of this level to achieve an
additional protective effect has been recognized in our
mouse model of hyperoxia-induced BPD, in terms of au-
tophagic flux [19].
PH is triggered in BPD by inflammation and endothe-
lial dysfunction, and greatly increases the mortality in
BPD patients [2]. Earlier studies have indicated a thera-
peutic benefit from bone marrow-derived MSCs in im-
proving respiratory function in animal models of PH
[67, 68]. We used non-invasive high-resolution echocardi-
ography, a useful technique in translating the findings
from preclinical evaluations to clinical meaningful conclu-
sions, to evaluate cardiovascular function and changes
after MSC-CM/EXO or TSG-6 injections in a BPD mouse
model. We show that BPD and associated PH can be re-
versed with UC-MSC-CM/EXO treatment. EXO and
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TSG-6 treatment decreases loss of peripheral blood vessels
and restrains the inflammation response, thus improving
heart function after hyperoxia-induced lung injury. Interest-
ingly, our result corresponds with the improved pulmonary
function testing results of hyperoxia-induced lung injury on
full-term MSC-EXO treatment reported earlier [17].
The preterm period in humans and early postnatal de-
velopments in rodents is the time of active oligodendro-
genesis, myelination and axonal organization in the
developing subcortical white matter. Neonatal hyperoxia
exposure in the mouse disrupts development of the white
matter by delaying the maturation of oligodendroglial
lineage [69, 70]. Hyperoxia exposure has also been found
to disrupt axon-oligodendrocyte integrity in the subcor-
tical white matter [71]. Astrocytes promote axonal growth
and deliver essential neurotrophic factors under both
physiological and pathophysiological conditions. Loss and/
or abnormal function of glial cells can contribute to neu-
rodegeneration [72, 73]. This study suggests an important
role of oligodendrocytes and astrocytes in BPD pathology.
MSCs have neuroprotective properties in experimental in-
jury models of the brain [62, 63, 74]. Another study dem-
onstrates that administration of neural stem cells into
PN2 neonatal brain shows a shift toward differentiation
into oligodendrocytes [75]. However, the molecular mech-
anism underlying the neuroprotective actions of EXO is
not well understood. We demonstrate that administration
of MSC-CM EXO at early postnatal days reverses hypo-
myelination and increases astrocytes indicating the poten-
tial of MSC secretome for the treatment of neurological
and neurodegenerative disease. Our study suggests that
EXO protein, TSG-6, in part, plays an important role in
neuroprotection in the BPD mouse model.
We have shown before that hyperoxia (95% oxygen) ex-
posure in newborn mice increases levels of IL-6 and
causes increased lung cell death [76]. This is in accord
with our earlier observation that exposure to hyperoxia in
a developmentally appropriate cell culture model leads to
enhanced IL-6 release and cell death [77]. Furthermore,
levels of IL-6, TNF-α and IL-1β are shown to be signifi-
cantly increased in tracheal aspirates of premature neo-
nates with an adverse outcome (BPD/death) [78–80]. We
demonstrate that administration of MSC-CM EXO or
TSG-6 decreases the proinflammatory cytokine IL-6 levels
in the BPD mice. Other proinflammatory cytokines like
TNF-α and IL-1β also show decreased levels in lung tissue
on administration of MSC-CM EXO or TSG-6. Decrease
in cell death in the BPD lung on TSG-6 administration
suggests that TSG-6 may partly prevent the lung injury in-
duced by BPD in neonatal mice probably via modulating
the expressions of proinflammatory cytokines such as IL-6
in the lung tissue. Further research is required to under-
stand the mechanism of cell death in the individual cell
types of the lung.
Our study provides an important step toward the pre-
clinical development of a cell-free therapeutic from
MSCs that might be effective in preterm human infants
at risk for developing BPD. Nevertheless, there are limi-
tations of this study that need to be addressed before
translation of the therapy to the clinical setting. More
details are required to identify other critical components
of EXO, be they protein, lipid or nucleic acid species,
which are involved in preservation of lung growth and
function in experimental BPD. Only one dose of
MSC-CM EXO/TSG-6 was selected for these studies
based on earlier studies and there is no dose–response
data. More preclinical studies on larger animals are
needed to standardize and identify a range of doses and
timing for the intervention along with the functional
assays.
Although we obtained EXO-enriched fraction using
the differential centrifugation protocol, as characterized
by its morphology, particle number and protein content,
more uniform standardized EXO production methods
are required for regulatory requirement and complete
characterization of the purified fraction. It is interesting
that we found similar therapeutic effects of preterm
MSC-CM EXO in our mouse model of BPD on adminis-
trating EXO purified by differential centrifugation when
compared to those purified by density gradient centrifu-
gation [17]. We did not show any therapeutic effect with
the 25 wks GA EXO-depleted MSC-CM fraction in our
BPD model, suggesting that any contaminating proteins
in EXO preparations could be inert excipients from the
pharmacological standpoint [81]. Thus, this preparation
could be used for the bench side work. However, for
large-scale clinical trials, optimal purity and consistency
of MSCs will be important, which will help in dosage
calculations and determination of the comprehensive
molecular and functional characterization of the active
MSC EXO factors [82]. More mechanistic information is
needed to better understand how preterm MSC-derived
EXO or TSG-6 work as a preventive or early therapeutic
approach for BPD. This will enable us to determine the
best clinical candidates with BPD for MSC-derived CM/
EXO/TSG-6 therapy.
Overall, our results suggest that a comprehensive
strategy involving MSC secretome or TSG-6 administra-
tion could benefit in amelioration of lung diseases, par-
ticularly BPD and its associated pathologies affecting the
heart and the brain. The present study gives an import-
ant lead for development of cell-free therapy for BPD
and other lung injury conditions.
Conclusions
The current study demonstrates for the first time that ad-
ministration of preterm hUC-derived MSC-CM EXO im-
proves BPD pathology of lung, heart and brain and reduces
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inflammation, at least in part, via exosomal factor TSG-6.
TSG-6, detected in the EXO fraction, on administration
decreases lung inflammation, alveolar-capillary leak, altered
morphometry and cell death in the BPD mouse model.
This was accompanied by an improvement in PH, pulmon-
ary vascular remodeling, and decreased brain pathology.
Moreover, the therapeutic effects of MSC-CM EXO were
abrogated by TSG-6 knockdown in the MSCs using
TSG-siRNA or by injecting TSG-6 NAb in the BPD mice
along with the treatment with EXO. This loss in thera-
peutic action was not observed by scrambled siRNA or Iso-
type control, respectively, indicating an important role of
TSG-6 in the treatment of hyperoxia-induced lung injury,
BPD. The proinflammatory cytokines IL-6, TNF-α and
IL-1β were decreased in EXO or TSG-6-treated BPD mice
suggesting its modulatory role in lung injury. These find-
ings suggest TSG-6 as one of the important protective me-
diator in therapies for BPD. This result may provide a
novel therapeutic approach for the treatment of BPD and
probably other pulmonary and neurological disorders.
Additional file
Additional file 1: Supplementary experimental procedures. Table S1.
Comparison of different parameters in the exosome dose. Table S2.
Clinical data for BPD and No BPD (n = 10). Figure S1. Preterm hUCs
MSCs, but not fibroblasts, improve the BPD pulmonary phenotype. i.p.
injections of MSCs from preterm (32 weeks) hUCs, in our mouse BPD
model, at PN2 and PN4 showed improvement in lung architecture (at
PN14), as evidenced by decreased chord length compared to the BPD
mice. Human primary dermal fibroblast (HDF) cells, injected as control
cells in the BPD mice, demonstrated no difference as compared to BPD
mice. All values are expressed as mean ± standard deviation (SD); four
experiments, N = 3 mice per group; one-way ANOVA with Tukey’s post
hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001. Figure S2. Isolation and
characterization of preterm UC-MSCs (A) UC-MSCs from 25 and 30 wks
gestational age UC, after Passage 1, 2 days (I, III) and 5 days (II, IV) in
culture respectively. The cells were adherent to the culture flasks and
displayed fibroblast-like morphology. (B) FACS characterization of UC-
MSCs. UC-MSCs were positive for CD105, CD73 and CD90 and were
negative for HLA-DR, CD19 and CD14. (C) Differentiation of UC-MSCs into
adipocytes (Oil Red O staining), osteocytes (Alizarin Red S staining) and
chondrocytes (Alcian Blue staining). Figure S3. (A-F). Isolation and identifi-
cation of hUC MSC-CM EXO (A) Transmission electron micrograph (TEM) of
hUC-MSC-EXO 25 wks (I) and 30 wks (II) depicts intact exosomes with a
diameter of 40–120 nm. Scale bar: 100 nm. (B) Particle number and size of
isolated exosomes by nanosight nanoparticle tracking analysis. Repre-
sentative plot of the 25wks EXO and 30 wks EXO, samples 1:50 and 1:20
diluted, respectively, for the analysis. (C) Dot blot of UC-MSC-CM 25
wks (I), UC-MSC-CM 25 wks EXO (II), UC-MSC-CM 30 wks (III), UC-MSC-
CM EXO 30 wks (IV), show positive signal for exosome-specific antibody
CD63 while no signal is detected in negative controls - DMEM:F12
media alone (V) or PBS (VI). (D) Dot blot of exosomal fractions [hUC-
MSC-CM EXO 25 wks (II), hUC-MSC-CM EXO 30 wks (IV)] did not show
any signal after probing with cytoskeletal membrane antibodies (TGN
48), which was otherwise detected in CM fractions [from 25 wks GA UC
(I) and 30 wks GA UC (III)] confirming the purity of the isolated exoso-
mal fraction. No signal was detected in negative controls - DMEM:F12
(V) and PBS (VI). (E) Detection of CD81 in UC-MSCs, MSC-CM and MSC-
CM EXO from 25 wks GA and 30 wks GA by Western blotting. Specific
signal (25 kDa) was detected for CD81 in all fractions containing exo-
somes. No signal was seen in the loading controls, DMEM:F12 and PBS.
Exosomal protein CD81 was also not detected in the EXO-depleted MSC-
CM. (F) Detection of exosomal protein Alix-1 (97 kDa) in exosomes derived
from 25 wks GA hUC MSCs by Western blotting. Figure S4. (A) Percentage
of macrophages in BALF. Histogram depicting the percentage of macro-
phages in the BALF of RA, BPD, DMEM:F12 or PBS-injected, MSC-CM or EXO
(25 wks-injected, 30 wks-injected) BPD mice at PN14. (B-C) Number of
triple points and quadruple points. Histogram depicting number of
triple points (B) and quadruple points (C) in lungs of RA, BPD,
DMEM:F12 or PBS-injected, MSC-CM or EXO (25 wks-injected, 30 wks-
injected) BPD mice at PN14. (D-E) Decreased hyperoxia-induced cell
death in lungs of hUC MSC-CM-treated BPD pups. (D) Representative
TUNEL immunofluorescence images of lung from the five experimental
groups, RA (I), BPD (II), BPD + DMEM:F12 (III), BPD + MSC-CM 25 wks (IV),
BPD + MSC-CM 30 wks (V). The nuclei are counterstained with DAPI. Ar-
rows depict TUNEL-positive dead cells (green) in the field. Scale bar: 50 μm.
(E) Histogram demonstrating the quantitative analysis of TUNEL-positive
cells, expressed as a percentage, as described in Additional Information
methods. All values are expressed as mean ± SEM; five experiments, N = 3–5
mice per group; one-way ANOVA with Tukey’s post hoc correction; *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Figure S5. Decreased
hyperoxia-induced cell death in lungs of hUC MSC-CM EXO-treated BPD
pups. (A) Representative TUNEL immunofluorescence images of lung
from the five experimental groups, RA (I), BPD (II), BPD + PBS (III), BPD +
MSC-CM EXO 25 wks (IV), BPD + MSC-CM EXO 30 wks (V). The nuclei are
counterstained with DAPI. Arrows depict TUNEL-positive dead cells
(green) in the field. Scale bar: 50 μm. (B) Histogram demonstrating the
quantitative analysis of TUNEL-positive cells, expressed as a percent-
age, as described in Additional Information methods. (C) Representa-
tive immunofluorescence images of lung from the five experimental
groups, RA (I), BPD (II), BPD + PBS (III), BPD + MSC-CM EXO 25 wks (IV),
BPD + MSC-CM EXO 30 wks (V) stained with cleaved caspase-3. The
nuclei are counterstained with DAPI. Arrows depict TUNEL-positive
dead cells (red) in the field. Scale bar: 50 μm. (D) Histogram demon-
strating the quantitative analysis of cleaved caspase-3 positive cells,
expressed as a percentage, as described in Additional Information methods.
All values are expressed as mean ± SEM; five experiments, N = 3–5 mice per
group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p <
0.01; ***p < 0.001; ****p < 0.0001. Figure S6. MSC-CM EXO rescue hyperoxia-
induced loss of peripheral pulmonary blood vessels (A) Representative
images of lung sections stained with endothelial cell marker CD31. Arrows
point to CD31 staining (green) in the blood vessels in the lungs of PN14
mice. The cells were counterstained with DAPI for nuclear staining. (B)
Quantitative analyses of mean pixel intensity of CD31 immunofluorescence
at PN14 in RA, BPD, PBS-injected and MSC-CM-EXO-injected BPD mice
groups. Scale bar: 100 μm. All values are expressed as mean ± SEM; five
experiments, N = 3–5 mice per group; one-way ANOVA with Tukey’s post
hoc correction; *p < 0.05; **p < 0.01. Scale bar: 50 μm. Figure S7. hUC MSC
secretome treatment decreases hyperoxia-induced cell death in the brain
of the BPD mice. (A-D) Histogram demonstrating the quantitative
analysis of TUNEL-positive cells, expressed as a percentage in the ol-
factory bulb (A), forebrain region (B), midbrain region (C) and hind-
brain (D) region of PN14 mouse brain after MSC-CM treatment. (E-H)
Histogram demonstrating the quantitative analysis of TUNEL-positive cells,
expressed as a percentage in the olfactory bulb (E), forebrain region (F),
midbrain region (G) and hindbrain (H) region of PN14 mouse brain after
MSC-CM EXO treatment. All values are expressed as mean ± SEM; five experi-
ments, N = 3–4 mice per group; one-way ANOVA with Tukey’s post hoc cor-
rection; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Figure S8. hUC
MSC-CM EXO-treated pups decreased loss of myelination and increased
GFAP expression in the brain of BPD mice. (A) Representative immunofluor-
escence images of MBP staining, marker for myelin, in RA, BPD, vehicle
(PBS)-injected BPD mice, MSC-CM EXO 25 wks and MSC-CM EXO 30 wks-
injected BPD mice (I, II, III, IV, V), to quantitate myelin loss in BPD and vehicle
(PBS)-injected BPD mice (II, III) and restoration of myelination after MSC-CM
EXO 25 wks (IV) and MSC-CM EXO 30 wks (V) injections. (B) Representative
immunofluorescence images of GFAP staining in RA, BPD, PBS + BPD and
MSC-CM EXO 25 wks and MSC-CM EXO 30 wks-injected BPD mice (I, II, III, IV,
V). ×400 magnification, Scale bar: 50 μm (C-D) Histogram showing quantita-
tion of MBP expression (C) and GFAP expression (D) in RA, BPD, BPD + PBS,
BPD +MSC-CM EXO 25 wks and BPD +MSC-CM EXO 30 wks groups. All
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values are expressed as mean ± SEM; five experiments, N = 3–4 in each
group; one-way ANOVA with Tukey’s post hoc correction; *p < 0.05; **p <
0.01, ***p < 0.001. Scale bar: 50 μm. Figure S9. EXO-depleted CM does not
reverse hyperoxia-induced lung morphometric alterations (A-D) Histogram
depicting number of branches (A), junctions (B), triple points (C), quadruple
points (D) in lungs of RA, BPD, DMEM:F12-, MSC-CM 25 wks- and EXO-
depleted MSC-CM 25 wks-injected BPD mice at PN14. All values are
expressed as mean ± SEM; five experiments, N = 3–5 mice per group; one-
way ANOVA with Tukey’s post hoc correction; *p< 0.05; **p < 0.01. Scale bar:
50 μm. Figure S10. Elevated levels of tumor necrosis factor-α-stimulated
gene-6 (TSG-6) in human BPD tracheal aspirate and lung tissue of the BPD
mouse model and its detection in EXO fraction (A) Relative TSG-6 expression
in the human lung tracheal aspirates (TA) from premature infants. Real-time
PCR demonstrates elevated levels of TSG-6 in the BPD samples compared to
the non-BPD samples. (B) Western blot quantitation of TSG-6 expression in
RA, BPD, BPD + PBS, BPD +MSC-CM EXO 25 wks, BPD +MSC-CM EXO 30 wks
groups at PN14. TSG-6 (~ 37 kDa) was detected by western blotting, and β-
actin was used as control for quantitation of TSG-6 expression by densitom-
etry. (C) Western blotting for detection of TSG-6 in MSC-CM and MSC-CM
EXO from 25 wks GA UC. PBS and DMEM:F12 were loaded as controls. TSG-6
is expressed in both CM and EXO from 25 wks GA UC. No signal was de-
tected in control samples used for vehicle injections, DMEM:F12 and PBS. β-
actin was used as a control to depict the cytoskeletal content in different
fractions. All values are expressed as mean ± SEM; N = 3–6 mice per group;
one-way ANOVA with Tukey’s post hoc correction; *p< 0.05; **p < 0.01.
Figure S11. TSG-6 treatment reverses morphometric alterations, decreases
cell death, and rescues hyperoxia-induced loss of peripheral pulmonary blood
vessels in the BPD mouse model. (A-B) Histogram depicting number of triple
points (A) and quadruple points (B) in lungs of RA, BPD, PBS-injected and
TSG-6 treated BPD mice at PN14. (C) Representative images of lung sections
stained with endothelial cell marker CD31. Arrows point to CD31 staining
(green) in the blood vessels in the lungs of RA (I), BPD (II), PBS-injected (III)
and TSG-6-treated (IV) BPD mice at PN14 mice. The cells were counterstained
with DAPI for nuclear staining. (D) Quantitative analyses of mean pixel inten-
sity of CD31 immunofluorescence at PN14 in RA, BPD, PBS-injected and TSG-
6-injected BPD mice groups. Scale bar: 100 μm. All values are expressed as
mean ± SEM; four experiments, N = 3–8 mice per group; one-way ANOVA
with Tukey’s post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001. Figure S12. TSG-6 treatment decreases hyperoxia-induced cell death
and reversed loss of myelination and increased GFAP expression in the brain
of BPD mice (A-D). Histogram demonstrating the quantitative analysis of
TUNEL-positive cells, expressed as a percentage (as described in Additional In-
formation methods) in the olfactory bulb region (A), forebrain region (B),
midbrain region (C), and hindbrain region (D) in RA, BPD, BPD+ PBS and BPD
+ TSG-6-injected PN14 mice brain. (E-H) TSG-6 administration attenuates de-
myelination and decrease in astrocytes in hyperoxia-induced lung injury (E)
Representative immunofluorescence images of MBP staining in RA, BPD, ve-
hicle (PBS)-injected BPD mice and TSG-6-injected BPD mice (I-IV) (F) Repre-
sentative immunofluorescence images of GFAP staining in RA, BPD, PBS +
BPD and TSG-6-injected groups (I-IV). ×400 magnification, Scale bar: 50 μm
(G) Histogram showing quantitation of MBP expression in RA, BPD, BPD +
PBS and TSG-6 groups. (H) Histogram showing quantitation of GFAP expres-
sion in RA, BPD, BPD + PBS and TSG-6 groups. All values are expressed as
mean ± SEM; four experiments, N = 3–8 mice per group; one-way ANOVA
with Tukey’s post hoc correction; *p < 0.05; **p < 0.01. Figure S13. (A) Histo-
gram depicting the percentage of macrophages in the BALF of RA, BPD, PBS-
injected, MSC-CM EXO 25 wks injected-, Isotype IgG+ EXO 25 wks injected-,
NAb TSG-6 + EXO 25 wks injected- BPD mice at PN14 (B) Graph
demonstrating PAAT values from the echocardiography of six experimental
groups RA, BPD, PBS-injected, MSC-CM EXO 25 wks injected-, Isotype IgG+
EXO 25 wks injected-, NAb TSG-6 + EXO 25 wks injected-BPD mice at PN14.
(C-D) Relative TSG-6 expression in 25 wks GA MSCs at different time points
after transfection with scr siRNA and TSG-6 siRNA, at the concentrations of
5 nM (C) and 10 nM (D). Real-time PCR was done to analyze the percentage
knockdown of TSG-6 after incubation with siRNA for 6 h, 16 h and 24 h. (E)
Histogram depicting the percentage of macrophages in the BALF of RA,
BPD, PBS injected-, MSC-CM EXO 25 wks injected-, scr siRNA EXO 25 wks
injected-, TSG-6 siRNA EXO 25 wks injected-BPD mice at PN14. (F) Graph
demonstrating PAAT values from the echocardiography of six experimental
groups RA, BPD, PBS injected-, MSC-CM EXO 25 wks injected-, scr siRNA EXO
25 wks injected-, TSG-6 siRNA EXO 25 wks injected-BPD mice at PN14. All
values are expressed as mean ± standard error of the mean (SEM); six
experiments, N = 3–6 mice per group; one-way ANOVA with Tukey’s
post hoc correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
(PDF 144 kb)
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